Request Deal Involvement

Novo Holdings, OrbiMed, and F-Prime Capital led a $100 million Series A financing round in OnCusp Therapeutics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Principals

ONCUSP THERAPEUTICS

target

ONCUSP THERAPEUTICS

NOVO HOLDINGS A/S

bidder

NOVO HOLDINGS A/S

ORBIMED ADVISORS LLC

bidder

ORBIMED ADVISORS LLC

CATALIO CAPITAL MANAGEMENT

bidder

CATALIO CAPITAL MANAGEMENT

FORGE LIFE SCIENCE PARTNERS

bidder

FORGE LIFE SCIENCE PARTNERS

BIOTRACK CAPITAL

bidder

BIOTRACK CAPITAL

F-PRIME CAPITAL

bidder

F-PRIME CAPITAL

SOFINNOVA INVESTMENTS

bidder

SOFINNOVA INVESTMENTS

MARSHALL WACE

bidder

MARSHALL WACE

BLACKBIRD BIOVENTURES

bidder

BLACKBIRD BIOVENTURES

CJNV BIOVENTURE

bidder

CJNV BIOVENTURE

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite